BRD4 Inhibitor-20

CAS No. 2490311-14-1

BRD4 Inhibitor-20( —— )

Catalog No. M35542 CAS No. 2490311-14-1

BRD4 Inhibitor-20 is a potent bromodomain protein 4 (BRD4) inhibitor with oral activity, demonstrating antiproliferative effects in cancer cell lines and used in studies of various cancers, including colon cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 58 Get Quote
5MG 88 Get Quote
10MG 145 Get Quote
25MG 273 Get Quote
50MG 412 Get Quote
100MG 567 Get Quote
500MG 1116 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BRD4 Inhibitor-20
  • Note
    Research use only, not for human use.
  • Brief Description
    BRD4 Inhibitor-20 is a potent bromodomain protein 4 (BRD4) inhibitor with oral activity, demonstrating antiproliferative effects in cancer cell lines and used in studies of various cancers, including colon cancer.
  • Description
    BRD4 Inhibitor-20 is a potent orally active bromodomain protein 4 (BRD4) inhibitor. BRD4 Inhibitor-20 has inhibitory activity for BRD4 (BD1) and BRD4 (BD2) with IC50 values of 19 nM and 28 nM, respectively. BRD4 Inhibitor-20 also has anti-proliferation activities in cancer cell lines. BRD4 Inhibitor-20 can be used for the research of kinds of cancer, such as colon cancer.
  • In Vitro
    BRD4 Inhibitor-20 (compound 12j) exhibits excellent BRD4 inhibitory activities (BD1, IC50=19 nM; BD2, IC50=28 nM) and inhibitory activities against BRD2 (BD1, IC50=24 nM; BD2, IC50=18 nM).BRD4 Inhibitor-20 (0.5, 2.5, 5.0 μM; 24 h) reduces the expression of c-Myc.BRD4 Inhibitor-20 (72 h) has anti-proliferation potency with IC50 values of 4.75 μM, 1.35 μM and 44.07 μM in HT-29, HL-60 and WI-38 cells, respectively.BRD4 Inhibitor-20 (2.5, 5.0, 10.0 μM; 24 h) can arrest the cell-cycle progression of HT-29 cells into the G1 phaseWestern Blot Analysis Cell Line:HT-29 cells Concentration:0.5, 2.5, 5.0 μM Incubation Time:24 h Result: Displayed profound inhibitory effects on c-Myc protein expression.Cell Proliferation Assay Cell Line:HT-29, HL-60 and WI-38 cells Concentration:Incubation Time:72 h Result:Possessed strong anti-proliferative activity and weak toxicity.Cell Cycle Analysis Cell Line:HT-29 cell lines Concentration:2.5, 5.0, 10.0 μM Incubation Time:24 h Result:Arrested the cell-cycle progression of the cell line into the G1 phases and the percentage of cells in G1 phase after treatment under concentrations of 2.5, 5.0 and 10.0 μM were 85.98%, 86.49% and 86.05%, respectively.
  • In Vivo
    BRD4 Inhibitor-20 (compound 12j) (i.v., 5 mg/kg; p.o, 15mg/kg) exhibits favorable oral pharmacokinetic propertie.
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2490311-14-1
  • Formula Weight
    358.41
  • Molecular Formula
    C18H18N2O4S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (348.76 mM; Ultrasonic (<60°C)
  • SMILES
    C(C)(C)=C1C=2C(NC1=O)=CC=C(NS(=O)(=O)C3=C(OC)C=CC=C3)C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yu Xu, et al. Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors. Eur J Med Chem. 2020 Dec 15;208:112780.?
molnova catalog
related products
  • GSK620

    GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.

  • dCBP-1

    dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.

  • BET bromodomain inhi...

    It is a BET bromodomain inhibitor.